Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial

Abstract: GSK2251052 is a boron-containing antimicrobial agent in clinical development for the treatment of serious Gram-negative bacterial infections. These GSK2251052 quality control (QC) studies were performed to establish ranges for control strains (broth microdilution [BMD] MIC and disk diffusion zones) as follows: Pseudomonas aeruginosa ATCC 27853 (2–8 μg/mL and 15–24 mm), Escherichia coli ATCC 25922 (0.5–2 μg/mL and 23–30 mm), Haemophilus influenzae ATCC 49247 (0.25–1 μg/mL and 22–31 mm), Streptococcus pneumoniae ATCC 49619 (0.25–1 μg/mL and 19–28 mm), Bacteroides fragilis ATCC 25285 (1–4 μg/mL [BMD] and 1–4 μg/mL [agar dilution]), and Bacteroides thetaiotaomicron ATCC 29741 (1–8 μg/mL [BMD] and 2–8 μg/mL [agar dilution]). These ranges, approved by Clinical and Laboratory Standards Institute, will be crucial in accurately evaluating GSK2251052 in vitro potency. [Copyright &y& Elsevier]